HEPPAPIG80

Liver cancer is the sixth most common cancer and the third most common cause of cancer-related deaths worldwide. Hepatocellular carcinoma (HCC) accounts for approximatively 90% of primary liver cancers. Surgery, comprising liver transplantation and liver resections, stands as the primary treatment modality for HCC. However, the recurrence rate is a main issue, being as high as 20% one year after resection and reaching 70% after 5 years. Preliminary data demonstrated that higher levels of hPG80 are associated with significantly lower survival, thus suggesting a prognostic value in this tumor type (Dupuy et al., Cancers, 2022). In addition, the hPG80 levels has not shown any significant difference among HCC patients with different BCLC stages, which may indicate a potential role of this biomarker in the early detection of relapse following liver surgery.

​

HEPPAPIG80 is an Italian, prospective, observational, monocentric study with longitudinal follow-up, in which patients with hepatocellular carcinoma that are planned to receive liver surgery (resection and/or transplantation) will be included. Blood samples will be taken during their treatment follow-up to evaluate plasma concentrations of hPG80.

​​

Study in partnership with the Niguarda hospital of Milan (Italia).

​

HEPPAPIG80 received a favorable opinion from the Italian Ethics Committee (Ethics Committee Milan Area 3, #404-09062022)

​

Current Status: Enrolling and Follow-up